Compare AdaptHealth Corp (AHCO) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs Ascendis Pharma A/S — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Ascendis Pharma A/S trades at $273.32 (market cap $17.51B). The key difference: Ascendis Pharma A/S is far larger — about 12.7× AdaptHealth Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | ASND | |
|---|---|---|
Market Cap | $1.38B | $17.51B |
Sector | Health | Health |
52-Week High | $13.38 | $274.50 |
52-Week Low | $8.68 | $163.32 |
Enterprise Value | $3.33B | $17.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
